Ibritumomab tiuxetan

DB00078

biotech approved investigational

Deskripsi

Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 0.8 hours (mammalian reticulocytes, in vitro)
Volume Distribusi Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines)
Klirens (Clearance) Approximately 7.2% of injected dose of yttrium Y 90 ibritumomab tiuxetan is excreted in urine within 7 days.

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Individuals taking these herbs/supplements while taking ibritumomab tiuxetan should be monitored for thrombocytopenia more frequently. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

802 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibritumomab tiuxetan.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibritumomab tiuxetan.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ibritumomab tiuxetan.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.
Alefacept The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.
Efalizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.
Daclizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.
Flunisolide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide.
Bortezomib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib.
Cladribine Ibritumomab tiuxetan may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine.
Amsacrine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin.
Bexarotene The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene.
Vindesine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine.
Floxuridine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine.
Indomethacin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indomethacin.
Tioguanine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine.
Vinorelbine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine.
Dexrazoxane The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate.
Sorafenib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib.
Streptozocin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan.

Target Protein

B-lymphocyte antigen CD20 MS4A1

Referensi & Sumber

Link

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Zevalin
    Kit • 1.6 mg/1mL • Intravenous • US • Approved
  • Zevalin
    Kit • 1.6 mg/1mL • Intravenous • US • Approved
  • Zevalin
    Injection; Kit • 1.6 mg/1mL • Intravenous • US • Approved
  • Zevalin
    Kit • 1.6 mg/ml • Intravenous • EU

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul